A detailed history of Virtus ETF Advisers LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 3,777 shares of BPMC stock, worth $356,359. This represents 0.14% of its overall portfolio holdings.

Number of Shares
3,777
Previous 3,096 22.0%
Holding current value
$356,359
Previous $286,000 15.03%
% of portfolio
0.14%
Previous 0.14%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$82.48 - $101.39 $56,168 - $69,046
681 Added 22.0%
3,777 $329,000
Q2 2024

Aug 14, 2024

SELL
$85.18 - $108.78 $123,511 - $157,731
-1,450 Reduced 31.9%
3,096 $333,000
Q1 2024

May 15, 2024

BUY
$73.17 - $99.79 $47,853 - $65,262
654 Added 16.8%
4,546 $431,000
Q4 2023

Feb 15, 2024

SELL
$43.96 - $92.84 $56,576 - $119,485
-1,287 Reduced 24.85%
3,892 $358,000
Q3 2023

Nov 07, 2023

SELL
$46.9 - $66.0 $31,376 - $44,154
-669 Reduced 11.44%
5,179 $260,000
Q2 2023

Aug 14, 2023

SELL
$42.2 - $66.37 $31,439 - $49,445
-745 Reduced 11.3%
5,848 $369,000
Q1 2023

May 15, 2023

BUY
$37.97 - $50.0 $4,518 - $5,950
119 Added 1.84%
6,593 $296,000
Q4 2022

Feb 14, 2023

BUY
$41.06 - $66.48 $53,747 - $87,022
1,309 Added 25.34%
6,474 $283,000
Q3 2022

Nov 14, 2022

BUY
$49.93 - $77.7 $3,794 - $5,905
76 Added 1.49%
5,165 $340,000
Q2 2022

Aug 12, 2022

BUY
$45.23 - $70.15 $60,020 - $93,089
1,327 Added 35.27%
5,089 $257,000
Q4 2021

Feb 14, 2022

SELL
$94.25 - $115.99 $145,145 - $178,624
-1,540 Reduced 29.05%
3,762 $403,000
Q3 2021

Nov 15, 2021

SELL
$80.98 - $109.47 $39,194 - $52,983
-484 Reduced 8.37%
5,302 $545,000
Q2 2021

Aug 10, 2021

BUY
$82.78 - $101.0 $37,416 - $45,652
452 Added 8.47%
5,786 $509,000
Q1 2021

May 17, 2021

BUY
$90.71 - $108.28 $13,243 - $15,808
146 Added 2.81%
5,334 $519,000
Q4 2020

Feb 12, 2021

SELL
$92.08 - $124.48 $292,261 - $395,099
-3,174 Reduced 37.96%
5,188 $582,000
Q3 2020

Nov 13, 2020

BUY
$66.45 - $92.7 $46,780 - $65,260
704 Added 9.19%
8,362 $775,000
Q2 2020

Aug 05, 2020

BUY
$57.09 - $79.27 $161,107 - $223,699
2,822 Added 58.35%
7,658 $597,000
Q1 2020

May 14, 2020

SELL
$48.11 - $82.22 $33,869 - $57,882
-704 Reduced 12.71%
4,836 $283,000
Q4 2019

Feb 13, 2020

BUY
$66.73 - $82.59 $183,107 - $226,626
2,744 Added 98.14%
5,540 $444,000
Q3 2019

Nov 12, 2019

SELL
$72.9 - $101.41 $11,299 - $15,718
-155 Reduced 5.25%
2,796 $205,000
Q2 2019

Aug 13, 2019

SELL
$73.54 - $97.8 $131,636 - $175,062
-1,790 Reduced 37.76%
2,951 $278,000
Q1 2019

May 14, 2019

SELL
$48.7 - $86.6 $30,340 - $53,951
-623 Reduced 11.61%
4,741 $380,000
Q4 2018

Feb 05, 2019

SELL
$45.57 - $74.26 $43,564 - $70,992
-956 Reduced 15.13%
5,364 $289,000
Q3 2018

Nov 14, 2018

SELL
$58.91 - $78.32 $266,273 - $354,006
-4,520 Reduced 41.7%
6,320 $493,000
Q2 2018

Aug 10, 2018

BUY
$60.96 - $101.18 $49,438 - $82,056
811 Added 8.09%
10,840 $688,000
Q1 2018

May 14, 2018

BUY
$73.28 - $102.95 $397,031 - $557,783
5,418 Added 117.5%
10,029 $920,000
Q4 2017

Feb 14, 2018

SELL
$62.91 - $88.32 $244,342 - $343,034
-3,884 Reduced 45.72%
4,611 $348,000
Q3 2017

Nov 14, 2017

BUY
$42.37 - $69.67 $32,921 - $54,133
777 Added 10.07%
8,495 $592,000
Q2 2017

Aug 14, 2017

BUY
N/A
7,718
7,718 $391,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.63B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.